Bavencio fails second ovarian cancer Phase III trial

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) discontinued the Phase III JAVELIN Ovarian 100 trial of Bavencio avelumab as first-line treatment of ovarian cancer after a planned interim analysis showed that the PD-L1 inhibitor would miss the primary endpoint of improving progression-free survival (PFS) vs. platinum-based chemotherapy alone.